Physician profile
Shawn Jindal
NPI 1437654944
$2,308.77
in general payments reported to CMS, 2019-2025
34 companies · $1,216 in 2025
The $1,216 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $257 · 2024: $835 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.77 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $315.47 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Exelixis INC. | $307.64 | 2024-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $240.12 | 2024-2025 | |
| Abbvie INC. | $213.77 | 2024-2025 | |
| Emd Serono, INC. | $166.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $136.58 | 2024-2025 | Enhertu, Calquence |
| Daiichi Sankyo INC. | $73.72 | 2025 | Enhertu |
| Pfizer INC. | $65.77 | 2024-2025 | |
| Taiho Oncology, INC. | $62.69 | 2025 | |
| Genmab U.S., INC. | $58.88 | 2024-2025 | Tivdak, Epkinly |
| Genzyme Corporation | $57.92 | 2025 | |
| Aveo Pharmaceuticals, INC. | $55.93 | 2025 | |
| Glaxosmithkline, LLC. | $54.55 | 2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $41.76 | 2024-2025 | Fruzaqla, Ninlaro |
| Incyte Corporation | $40.54 | 2025 | Jakafi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $38.28 | 2025 | |
| Jazz Pharmaceuticals INC. | $36.67 | 2024-2025 | |
| Janssen Biotech, INC. | $36.60 | 2025 | Balversa, Akeega, Erleada |
| Novocure INC. | $27.75 | 2025 | Optune Lua (Novottf-200t) |
| Tempus Ai, INC | $27.20 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.23 | 2025 | |
| Genentech USA, INC. | $22.48 | 2024 | Polivy |
| Beigene USA, INC. | $20.65 | 2024 | Brukinsa |
| Cycle Pharmaceuticals INC | $19.40 | 2025 | Phyrago |
| Mirati Therapeutics, INC. | $19.00 | 2024 | Krazati |
| Blueprint Medicines Corporation | $18.92 | 2024 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $18.41 | 2025 | Qinlock, Romvimza |
| Adc Therapeutics America, INC. | $17.16 | 2025 | |
| Celgene Corporation | $16.76 | 2025 | Reblozyl |
| Sobi, INC | $15.64 | 2025 | |
| Adaptive Biotechnologies Corporation | $15.16 | 2025 | Clonoseq |
| Puma Biotechnology, INC. | $14.86 | 2025 | |
| Merck Sharp & Dohme LLC | $14.83 | 2024 | Keytruda |
| Tactile Systems Technology INC | $13.83 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.